NCT03907540View on ClinicalTrials.gov

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

May 20, 2019

Study Completion Date

May 20, 2019

Conditions
Autoimmune DiseasesFibrosis
Interventions
DRUG

Belumosudil 200 mg tablet

Belumosudil 200 mg tablet, development candidate

DRUG

[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose

test investigational medicinal product

DRUG

[14C]-KD025 200 mg capsule

test investigational medicinal product

Trial Locations (1)

NG11 6JS

Quotient Sciences Ltd, Ruddington

All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Kadmon Corporation, LLC

INDUSTRY

NCT03907540 - Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 | Biotech Hunter | Biotech Hunter